Literature DB >> 25992361

The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.

Austin John Barrett1, Catherine M Bollard1.   

Abstract

Entities:  

Year:  2015        PMID： 25992361      PMCID： PMC4402608          DOI： 10.3978/j.issn.2305-5839.2015.01.18

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  28 in total

1.  Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.

Authors:  Emily Blyth; Leighton Clancy; Renee Simms; Chun K K Ma; Jane Burgess; Shivashni Deo; Karen Byth; Ming-Celine Dubosq; Peter J Shaw; Kenneth P Micklethwaite; David J Gottlieb
Journal:  Blood       Date:  2013-02-22       Impact factor: 22.113

2.  Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

Authors:  Tobias Feuchtinger; Kathrin Opherk; Wolfgang A Bethge; Max S Topp; Friedhelm R Schuster; Eva M Weissinger; Mohamad Mohty; Reuven Or; Michael Maschan; Michael Schumm; Klaus Hamprecht; Rupert Handgretinger; Peter Lang; Hermann Einsele
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

3.  Donor T cells to treat EBV-associated lymphoma.

Authors:  H E Heslop; M K Brenner; C M Rooney
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

4.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Authors:  Ekaterina Doubrovina; Banu Oflaz-Sozmen; Susan E Prockop; Nancy A Kernan; Sara Abramson; Julie Teruya-Feldstein; Cyrus Hedvat; Joanne F Chou; Glenn Heller; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Diane George; Ann Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Andromachi Scaradavou; Trudy N Small; Ramzi Khalaf; James W Young; Richard J O'Reilly
Journal:  Blood       Date:  2011-12-02       Impact factor: 22.113

5.  Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

Authors:  Juliet N Barker; Ekaterina Doubrovina; Craig Sauter; Jennifer J Jaroscak; Miguel A Perales; Mikhail Doubrovin; Susan E Prockop; Guenther Koehne; Richard J O'Reilly
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

6.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

7.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Authors:  G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard
Journal:  Leukemia       Date:  2013-03-01       Impact factor: 11.528

8.  Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

Authors:  Anastasia Papadopoulou; Ulrike Gerdemann; Usha L Katari; Ifigenia Tzannou; Hao Liu; Caridad Martinez; Kathryn Leung; George Carrum; Adrian P Gee; Juan F Vera; Robert A Krance; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen
Journal:  Sci Transl Med       Date:  2014-06-25       Impact factor: 17.956

9.  Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

Authors:  Ann M Leen; Anne Christin; Gary D Myers; Hao Liu; Conrad R Cruz; Patrick J Hanley; Alana A Kennedy-Nasser; Kathryn S Leung; Adrian P Gee; Robert A Krance; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  Blood       Date:  2009-08-21       Impact factor: 22.113

10.  The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.

Authors:  Natasha A Jain; Kit Lu; Sawa Ito; Pawel Muranski; Christopher S Hourigan; Janice Haggerty; Puja D Chokshi; Catalina Ramos; Elena Cho; Lisa Cook; Richard Childs; Minoo Battiwalla; A John Barrett
Journal:  Cytotherapy       Date:  2014-05-13       Impact factor: 5.414
View more
  10 in total

1.  Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.

Authors:  Greg D Whitehill; Shoba Amarnath; Pawel Muranski; Keyvan Keyvanfar; Minoo Battiwalla; Austin J Barrett; Dhanalakshmi Chinnassamy
Journal:  Mol Ther       Date:  2016-07-06       Impact factor: 11.454

2.  MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

Authors:  Corinna La Rosa; Jeff Longmate; Joy Martinez; Qiao Zhou; Teodora I Kaltcheva; Weimin Tsai; Jennifer Drake; Mary Carroll; Felix Wussow; Flavia Chiuppesi; Nicola Hardwick; Sanjeet Dadwal; Ibrahim Aldoss; Ryotaro Nakamura; John A Zaia; Don J Diamond
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

Review 3.  Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection.

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

4.  Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis.

Authors:  Xi-Zhi J Guo; Pradyot Dash; Matthew Calverley; Suzanne Tomchuck; Mari H Dallas; Paul G Thomas
Journal:  Mol Ther Methods Clin Dev       Date:  2016-01-27       Impact factor: 6.698

Review 5.  Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications.

Authors:  Monica Reis; Justyna Ogonek; Marsela Qesari; Nuno M Borges; Lindsay Nicholson; Liane Preußner; Anne Mary Dickinson; Xiao-Nong Wang; Eva M Weissinger; Anne Richter
Journal:  Front Immunol       Date:  2016-11-14       Impact factor: 7.561

Review 6.  Cytomegalovirus in Haematological Tumours.

Authors:  Sara Alonso-Álvarez; Enrique Colado; Marco A Moro-García; Rebeca Alonso-Arias
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

7.  Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL.

Authors:  María Fernanda Lammoglia Cobo; Julia Ritter; Regina Gary; Volkhard Seitz; Josef Mautner; Michael Aigner; Simon Völkl; Stefanie Schaffer; Stephanie Moi; Anke Seegebarth; Heiko Bruns; Wolf Rösler; Kerstin Amann; Maike Büttner-Herold; Steffen Hennig; Andreas Mackensen; Michael Hummel; Andreas Moosmann; Armin Gerbitz
Journal:  PLoS Pathog       Date:  2022-04-22       Impact factor: 7.464

Review 8.  Virus-Specific T Cells for the Immunocompromised Patient.

Authors:  Amy Houghtelin; Catherine M Bollard
Journal:  Front Immunol       Date:  2017-10-11       Impact factor: 7.561

9.  Massively parallel interrogation and mining of natively paired human TCRαβ repertoires.

Authors:  Matthew J Spindler; Ayla L Nelson; Ellen K Wagner; Natasha Oppermans; John S Bridgeman; James M Heather; Adam S Adler; Michael A Asensio; Robert C Edgar; Yoong Wearn Lim; Everett H Meyer; Robert E Hawkins; Mark Cobbold; David S Johnson
Journal:  Nat Biotechnol       Date:  2020-03-16       Impact factor: 54.908

Review 10.  Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target.

Authors:  Queenie Fernandes; Maysaloun Merhi; Afsheen Raza; Varghese Philipose Inchakalody; Nassima Abdelouahab; Abdul Rehman Zar Gul; Shahab Uddin; Said Dermime
Journal:  Front Oncol       Date:  2018-07-06       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.